Form 4 for ALT Altimmune, Inc.
Accepted 2024-08-20 00:00:00 ET · period of report 2024-08-19 · accession 0001104659-24-091346 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2024-08-20 | 2024-08-19 | ALT | Drutz David | Dir | M - OptEx | $2.55 | +41.8K | 49.8K | +520% | +$106.4K |
| DMI | 2024-08-20 | 2024-08-19 | ALT | Drutz David | Dir | S - Sale+OE | $6.90 | -16.0K | 55.5K | -22% | -$110.5K |
| DM | 2024-08-20 | 2024-08-19 | ALT | Drutz David | Dir | M - OptEx | $0.00 | -41.8K | 4,350 | -91% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 | 2024-08-19 | M | A | 21,750 | $2.50 | 63,708 | I See Footnote | — | — | (F1) Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC. (F2) Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. |
| 2 | Common | Common Stock, par value $0.0001 | 2024-08-19 | S | D | 7,827 | $6.93 | 41,958 | I See Footnote | — | — | (F3) This sale represents shares sold to cover the exercise price. (F2) Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. |
| 3 | Common | Common Stock, par value $0.0001 | 2024-08-19 | M | A | 20,000 | $2.60 | 49,785 | I See Footnote | — | — | (F1) Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC. (F2) Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. |
| 4 | Common | Common Stock, par value $0.0001 | 2024-08-19 | S | D | 8,184 | $6.88 | 55,524 | I See Footnote | — | — | (F3) This sale represents shares sold to cover the exercise price. (F2) Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. |
| 5 | Derivative | Stock Options (option to buy) | 2024-08-19 | M | D | 20,000 | $0.00 | 0 | D | $2.60 · — to 2029-01-02 | 20,000 Common Stock, par value $0.0001 | (F4) The shares underlying the option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date. |
| 6 | Derivative | Stock Options (option to buy) | 2024-08-19 | M | D | 21,750 | $0.00 | 4,350 | D | $2.50 · — to 2033-09-28 | 21,750 Common Stock, par value $0.0001 | (F5) The shares underlying the option became vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. |